Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Protokylol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 15/20 | 0.74 |
| ▸ | ADRB1 | P08588 | 14/20 | 0.74 |
| ▸ | ADRB3 | P13945 | 13/20 | 0.74 |
| ▸ | ADRA1D | P25100 | 10/20 | 0.74 |
| ▸ | ADRA1A | P35348 | 10/20 | 0.74 |
| ▸ | ADRA1B | P35368 | 10/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | CASP3 | P42574 | 1/20 | 0.54 |
| ▸ | CASP6 | P55212 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Protokylol SCHEMBL50567 | 0.99 | ADRB2 (0.76) | ADRB2ADRB1ADRB3ADRA1DADRA1A | |
| Protokylol SCHEMBL523029 | 0.97 | ADRB2 (0.73) | ADRB2ADRB1ADRB3ADRA1DADRA1A | |
| SCHEMBL11191804 | 0.86 | ADRB2 (0.68) | ADRB2ADRB1ADRB3ADRA1DADRA1A | |
| SCHEMBL11670365 | 0.86 | ADRB3 (0.70) | ADRB2ADRB1ADRB3ADRA1DADRA1A | |
| SCHEMBL7154315 | 0.84 | ADRB2 (0.68) | ADRB2ADRB1ADRB3ADRA1DADRA1A | |
| SCHEMBL7154320 | 0.84 | ADRB2 (0.68) | ADRB2ADRB1ADRB3ADRA1DADRA1A | |
| Hydrochloric Acid SCHEMBL11086014 | 0.82 | ADRB2 (0.60) | ADRB2ADRB1ADRB3ADRA1DADRA1A | |
| Protokylol SCHEMBL3716556 | 0.82 | ADRB2 (0.53) | ADRB2ADRB1ADRB3ADRA1DADRA1A | |
| SCHEMBL8305498 | 0.81 | ADRB3 (0.68) | ADRB2ADRB1ADRB3ADRA1DADRA1A | |
| SCHEMBL8305494 | 0.81 | ADRB3 (0.68) | ADRB2ADRB1ADRB3ADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060258735-A1 | 1,3-Bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders | MENG CHARLES Q | 2006-11-16 | — | — | US | claimed |
| EP-1330459-B1 | TRIPTOLIDE ANALOGS FOR THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | UNIV EMORY (US) | 2006-08-02 | — | — | EP | claimed |
| US-7078431-B2 | 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders | ATHEROGENICS, INC. (US) | 2006-07-18 | — | — | US | claimed |
| US-6777441-B2 | FOR THERAPY AND PROPHYLAXIS | EMORY UNIVERSITY | 2004-08-17 | — | — | US | claimed |
| US-20030236298-A1 | 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders | ATHEROGENICS PHARMACEUTICALS, INC. | 2003-12-25 | — | — | US | claimed |
| US-6608101-B1 | Inflammatory disorders; 3-(2,4-dimethoxy-5-(thien-2-yl)phenyl)-1-(4-carboxymethoxy-3,5 -dimethoxyphenyl)-2-propen-1-one; | ATHEROGENICS, INC. | 2003-08-19 | — | — | US | claimed |
| EP-1330448-A2 | 1,3-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND THEIR USE TO TREAT VCAM-1 MEDIATED DISORDERS | Atherogenics, Inc. (US) | 2003-07-30 | — | — | EP | claimed |
| WO-2001098291-A2 | 1,3-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND THEIR USE TO TREAT VCAM-1 MEDIATED DISORDERS | ATHEROGENICS, INC. (US) | 2001-12-27 | — | — | WO | claimed |
| US-20240145031-A1 | Methods and devices for drug repositioning and drug repurposing as nuclear receptor modulators | Precision Medicine Lab (NL) | 2024-05-02 | — | — | US | disclosed |
| US-20210290771-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-09-23 | — | — | US | disclosed |
| US-11052046-B2 | Method for preparing micro-particles by double emulsion technique | NANOMI B.V. (NL) | 2021-07-06 | — | — | US | disclosed |
| US-11000597-B2 | Engineered receptor/ligand system for delivery of therapeutic agents | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-05-11 | — | — | US | disclosed |
| US-20210015752-A1 | METHODS FOR PRODUCING PARTICLES OF AN ACTIVE INGREDIENT | SAVIOR LIFETEC CORPORATION (TW) | 2021-01-21 | — | — | US | disclosed |
| EP-3687503-A1 | METHOD FOR PREPARING MICRO-PARTICLES BY DOUBLE EMULSION TECHNIQUE | Nanomi B.V. (NL) | 2020-08-05 | — | — | EP | disclosed |
| EP-0145240-B1 | METHOD FOR PRODUCING MICROCAPSULE | Takeda Chemical Industries, Ltd. (JP) | 1989-04-19 | — | — | EP | disclosed |
| US-4711782-A | Prolonged release microcapsules and their production | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-12-08 | — | — | US | disclosed |
| US-4652441-A | WATER SOLUBLE DRUGS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-03-24 | — | — | US | disclosed |
| EP-0190833-A2 | Method for producing microcapsule | Takeda Chemical Industries, Ltd. (JP) | 1986-08-13 | — | — | EP | disclosed |
| EP-0145240-A2 | Method for producing Microcapsule | Takeda Chemical Industries, Ltd. (JP) | 1985-06-19 | — | — | EP | disclosed |
| EP-0103830-A2 | Phenylethylemine derivatires as growth stimulators | BAYER AG (DE) | 1984-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236298-A1 | 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders | VCAM1, ICAM1, ITGB1 | ADRB2 86/4885ADRB1 24/4885ADRB3 163/4885 |
| US-20060258735-A1 | 1,3-Bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders | VCAM1, ICAM1, ITGB1 | ADRB2 86/4885ADRB1 24/4885ADRB3 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.